Call for Abstracts

Abstracts submitted for presentation in the EORTC-NCI-AACR Symposium will be reviewed by an international panel of experts in the field of the subject and will be judged solely on the data submitted. The final decision on the presentation format of all selected abstracts lies at the sole discretion of the Scientific Committee.

Abstracts submitted after the stipulated deadline will not be considered.

Authors are strongly advised to submit prior to the deadline and avoid unnecessary delays which may affect the standing of their abstract.

In case of any abstract related queries please contact:

Submitting an abstract for presentation in the 32nd EORTC-NCI-AACR symposium does not constitute registration for the event. When selected, abstract presenters must register to attend the 32nd EORTC-NCI-AACR symposium.

The presenting author will receive the result of the review and the Scientific Committee’s decision on their abstract by email at the latest by mid-September 2020.

Abstract Submission is now closed.

Late Breaking Abstract Submission: 17-24 September 2020

ENA 2020 - Poster panel
The following presentation formats are applicable at the EORTC-NCI-AACR Symposium:

Abstract Topics

  • Angiogenesis and vascular disrupting agents

  • Animal Models

  • Antibody-drug Conjugates

  • Apoptosis Inducers

  • Cancer Genomics

  • Cellular Therapies

  • Chemoprevention

  • Combination Therapies

  • Combinatorial Chemistry

  • Cytotoxics (including Antimetabolites, Anthracyclin, Alkylating agents, Aurora kinases, Polo-like kinase, Topos-isomerase inhibitors, Tubulin-binding compounds)

  • DNA Repair Modulation (including PARP, CHK, ATR, ATM)

  • Drug Delivery

  • Drug Design

  • Drug Resistance and Modifiers

  • Drug Screening

  • Epigenetic modulators (HDAC Bromodomain modulators, EZH2)

  • Functional Genomics

  • Immune checkpoints

  • Molecular Targeted Agents

  • New Agents for Paediatric Oncology

  • New Drugs

  • New Therapies in Immuno Oncology

  • Oncolytic Viruses and Vaccination

  • Preclinical Models

  • Other

  • Radiation Interactive Agents

  • Tumour immunology and Inflammation